<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646501</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0743</org_study_id>
    <nct_id>NCT02646501</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Clinical Trial for Effect of Stellate Ganglion Block in Medically Refractory Ventricular Tachycardia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will compare the effects of PSGB(percutaneous stellate ganglion block) in
      patients with recurrent sustained VT/VF in spite of appropriate medical therapy and
      cardio-version/ defibrillation after correction of underlying correctable factors with those
      without PSGB by prospective randomized trail. PSGB will be performed every 3 days by
      anesthesiology specialist after cardiologist's request, until the stabilization of VT/VF. We
      will compare the frequency and episode number of VT/VF, procedure related complication, acute
      and long-term mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent ventricular tachycardia(VT)/ fibrillation(VF) increases mortality, especially in
      patients with structural heart disease. It has been reported that cardiac sympathectomy
      reduces VT/VF episodes in patients with complex VT, long QT syndrome, catecholaminergic
      polymorphic VT, or myocarditis. However, cardiac sympathectomy operation is hard to conduct
      in patients with hemodynamically unstable recurrent VT/VF or electrical storm. Therefore, we
      hypothesized that bed-side percutaneous stellate ganglion block (PSGB) reduces VT/VF episodes
      and mortality in patients with repetitive VT/VF who are properly managed with optimal medical
      therapies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of VT/VF episodes after randomization</measure>
    <time_frame>5 days after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of VT/VF episodes after randomization</measure>
    <time_frame>5 days after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>1 month after the enrollment</time_frame>
    <description>death, cause of death,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure related complication</measure>
    <time_frame>1 month after the enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractory Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>group A+PSGB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Antiarrhythmic drug + percutaneous stellate ganglion block) group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiarrhythmic drug group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drug</intervention_name>
    <arm_group_label>group A+PSGB</arm_group_label>
    <arm_group_label>group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>percutaneous stellate ganglion block (PSGB)</intervention_name>
    <arm_group_label>group A+PSGB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients agreement of consent

          -  AF patient age 20-85

          -  Patient are diagnosed Refractory Ventricular tachycardia

          -  Patients who have generated Refractory Ventricular tachycardia despite of
             defibrillation and drug therapy

          -  Patients with ICD have generated ICD shock or anti-tachycardia pacing despite of
             defibrillation and drug therapy

        Exclusion Criteria:

          -  Patients who do not agree with study inclusion

          -  Patients who do not taken stellate ganglion block due to unstable hemodynamic status

          -  Patients have experienced major hemorrhagic complication

          -  Patients of the DNR status

          -  Patients with malignancy tumor, major neurogenic disease or gastrointestinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui-Nam Park, MD, Ph.D</last_name>
    <phone>82-2-2228-8459</phone>
    <email>hnpak@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Cardiovascular Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Nam Pak, M.D., Ph.D.</last_name>
      <phone>82-2-2228-8459</phone>
      <email>hnpak@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

